InMed Pharmaceuticals Inc.

NASDAQ: INM · Healthcare · Biotechnology

Canadian filerHQ Vancouver, BCCIK 0001728328Reports USD

#705 of 1,394 Healthcare companies by revenue53rd-percentile growth

EA Score

45D

FH 41DQ 45GM 57SS 41

v0.1 · 65/100 weight · provisional

↑ balance-sheet leverage, 3-yr revenue growth · ↓ Piotroski F, disclosure history

Methodology →

Revenue TTM

$4.0M

Rev growth YoY (TTM)

-18.3%

Net income (FY)

-$8.2M

Employees

Market cap

$2.8M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$4.9M$4.9M2025

Net income-$8.2M-$8.2M2025

Operating income-$7.9M-$7.9M2023

Total assets$15.6M$15.6M2025

Liabilities$2.1M$2.1M2025

Equity$13.4M$13.4M2025

Revenue trend

FY2022 – FY2025 · USD

$1.9M

FY22

$1.4M

FY22

$1.4M

FY23

$4.6M

FY24

$4.9M

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

InMed Pharmaceuticals Inc. booked $4.9M in FY2025 revenue, growing 7.5% year over year — about the middle of the pack among Healthcare companies we track, at a -165.1% net margin.

Peers · Healthcare

Bioxytran, Inc.28D Dogwood Therapeutics, Inc.——Adial Pharmaceuticals, Inc.——Hypha Labs, Inc.35D

Key facts

CEOEric A. Adams Chem.

SectorHealthcare

IndustryBiotechnology

HeadquartersVancouver, BC

ExchangeNASDAQ: INM

Employees13

IPO date2014-05-05

Latest filings

8-K2026-07-10 8-K2026-06-10 8-K2026-05-19 8-K2026-05-19 8-K2026-05-07 10-Q2026-05-06 8-K2026-04-27 8-K2026-04-03

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.